Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment †

Pitsiu, Maria; Wilmer, Alexander; Bodenham, A.; Breen, D; Bach, V.; Bonde, Jan; Kessler, Paul D.; Albrecht, Susanne; Fisher, Gail; Kirkham, Andrew J. T.

doi:10.1093/bja/aeh086

Cited by 75 publications

(49 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, some indicators such as t 1 2 ,α = 1.85h, t 1 2 ,β = 12.2h, V ml = 0.626 4 were calculated in accordance with results in Ref. [26]. Pharmacokinetics of remifentanil acid for patients with severe degree of renal impairment will be studied in the future.…”

Section: Applying Laplace Transform To Pharmacokinetics Of Remifentanmentioning

confidence: 57%

“…As a new analgesic used in Chinese hospitals, its pharmacokinetics in Chinese population is not yet thoroughly studied. One-, two-and three-compartment models have previously been used to the pharmacokinetics of remifentanil in humans [25,26] . A two-compartment model was used in patients with mild degrees of renal impairment without theoretical deduction.…”

Section: Application Of Pkain Algorithm To Parameter Optimization Of mentioning

confidence: 99%

See 1 more Smart Citation

Parameter optimization of pharmacokinetics based on artificial immune network

Liu

Zhou

et al. 2008

Appl. Math. Mech.-Engl. Ed.

View full text Add to dashboard Cite

A new method for parameter optimization of pharmacokinetics based on an artificial immune network named PKAIN is proposed. To improve local searching ability of the artificial immune network, a partition-based concurrent simplex mutation is developed. By means of evolution of network cells in the PKAIN artificial immune network, an optimal set of parameters of a given pharmacokinetic model is obtained. The Laplace transform is applied to the pharmacokinetic differential equations of remifentanil and its major metabolite, remifentanil acid. The PKAIN method is used to optimize parameters of the derived compartment models. Experimental results show that the twocompartment model is sufficient for the pharmacokinetic study of remifentanil acid for patients with mild degree of renal impairment.

show abstract

Section: Applying Laplace Transform To Pharmacokinetics Of Remifentanmentioning

confidence: 57%

Section: Application Of Pkain Algorithm To Parameter Optimization Of mentioning

confidence: 99%

Parameter optimization of pharmacokinetics based on artificial immune network

Liu

Zhou

et al. 2008

Appl. Math. Mech.-Engl. Ed.

View full text Add to dashboard Cite

show abstract

“…In the elderly remifentanil clearance is reduced (Minto et al 1997b). This observation, associated with the well-known increase of elderly patients' susceptibility to the pharmacological action of opioids, should lead to markedly decreased dosing recommendations in this population (Kabbaj et al 2005;Pitsiu et al 2004;Bouillon et al 2002).…”

Section: Pharmacokineticsmentioning

confidence: 99%

“…It is excreted through the kidney. Even when accumulation occurs in renal failure patients, the concentrations obtained after a few hours of infusion are insufficient to generate pharmacological effects (Hoke et al 1997;Pitsiu et al 2004). Scott et al (1991), Gepts et al (1995), Maitre et al (1987) and Minto et al (1997) for fentanyl, sufentanil, alfentanil and remifentanil…”

Section: Active Metabolitementioning

confidence: 99%

Remifentanil and Other Opioids

Servin

Billard

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Most opioids used in anaesthesia are of the anilidopiperidine family, including fentanyl, alfentanil, sufentanil and remifentanil. While all share similar pharmacological properties, remifentanil, the newest one, is probably the most original, which is the reason this review focusses especially on this drug. Remifentanil is a potent mu-agonist that retains all the pharmacodynamic characteristics of its class (regarding analgesia, respiratory depression, muscle rigidity, nausea and vomiting, pruritus, etc.) but with a unique pharmacokinetic profile that combines a short onset and the fastest offset, independent of the infusion duration. Consequently, it offers a unique titratability when its effects need to be quickly achieved or suppressed, but it requires specific drug delivery schemes such as continuous infusion, target-controlled infusion and anticipated postoperative pain treatment. Kinetic differences between opioids used in anaesthesia and some clinical uses of remifentanil are reviewed in this chapter.

show abstract

“…The context half-life of remifentanyl is 2 -3 min and is independent of the duration of infusion. Remifentanyl is eliminated via the kidneys, and its elimination is prolonged in patients with severe renal impairment [4,5]. The determination of analgesics -anaesthetics in biological fluids is of major clinical importance in order to accurately monitor their concentration levels and assist/stir therapeutic intervention.…”

Section: Introductionmentioning

confidence: 99%

Analysis of anaesthetics and analgesics in human urine by headspace SPME and GC

Raikos

Theodoridis²,

Alexiadou

et al. 2009

J of Separation Science

View full text Add to dashboard Cite

The determination of widely used anaesthetic and analgesic drugs in biological fluids is of major clinical importance. Typical methods used for sample preparation employ liquid-liquid extraction protocols which are complex, costly, not handy and not amenable to automation. In the present communication, we report the development of a methodology that employs headspace solid-phase microextraction (HS-SPME) for the determination of four anaesthetic (lidocaine, midazolam, diazepam and ketamine) and three analgesic drugs (fentanyl, remifentanyl and codeine) in human urine. Important parameters controlling SPME were studied: selection of SPME fibre, type and amount of salt added, preheating and extraction time, extraction temperature, sample volume and desorption time. GC with nitrogen phosphorus detection (GC-NPD) facilitates sensitive and selective detection of the anaesthetics. The developed method renders an efficient tool for the precise and sensitive determination of the anaesthetics and analgesics in human urine (RSDs ranged from 7.7 to 12.6%, whereas LODs ranged from 0.01 to 1.5 ng/mL). The method was applied to the determination of the anaesthetics and analgesics in human urine from patients that had undergone coronary by-pass surgery operations. The proposed protocol can function as an attractive alternative for clinical acute intoxications and medico-legal cases.

show abstract

Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment †

Cited by 75 publications

References 20 publications

Parameter optimization of pharmacokinetics based on artificial immune network

Parameter optimization of pharmacokinetics based on artificial immune network

Remifentanil and Other Opioids

Analysis of anaesthetics and analgesics in human urine by headspace SPME and GC

Contact Info

Product

Resources

About